Abstract:Background and Purpose Targeting macrophage but not hepatocyte liver X receptors (LXRs) can reduce atherosclerosis without effect on hepatic lipogenesis. In this study, we encapsulated LXR ligands with D-Nap-GFFY to form a nanofibre hydrogel (D-Nap-GFFY-T0901317 or GFFY-T0901317) and determined its effect on atherosclerosis, hepatic lipogenesis and the underlying mechanisms involved. Experimental Approach D-Nap-GFFY-T0901317 was subcutaneously injected to proatherogenic diet-fed apoE-deficient (Apoe(-/-)) mice, followed by determination of the development of atherosclerosis, liver steatosis and the involved mechanisms, with comparison of T0901317 oral administration. Key Results Subcutaneous injection of D-Nap-GFFY-T0901317 to Apoe(-/-) mice inhibited atherosclerosis at a comparable level as T0901317 oral administration without effect on hepatic lipogenesis. More importantly, D-Nap-GFFY-T0901317 regressed the advanced lesions. In arterial wall, D-Nap-GFFY-T0901317 reduced macrophage/foam cells, necrotic cores and calcification and increased collagen content. It activated expression of ABCA1/G1 and smooth muscle alpha-actin, while inhibiting expression of intracellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1). D-Nap-GFFY-T0901317 also reduced serum pro-inflammatory cytokines and facilitated Kupffer cell M2 polarization. Mechanistically, D-Nap-GFFY-T0901317 was selectively taken up by macrophages but not hepatocytes, resulting in activation of macrophage ABCA1/G1 expression, while having no effect on lipogenic genes in hepatocytes. Moreover, the selective uptake of D-Nap-GFFY-T0901317 by macrophages was mainly completed in a scavenger receptor class A-dependent manner. Conclusion and Implications Our study demonstrates that D-Nap-GFFY-T0901317 reduces atherosclerosis without effect on hepatic lipogenesis by targeting macrophage LXRs selectively, indicating its potential application for atherosclerosis treatment.

A novel small molecule liver X receptor transcriptional regulator, nagilactone B, suppresses atherosclerosis in apoE-deficient mice.

The Effect of T0901317 on ATP-binding Cassette Transporter A1 and Niemann-Pick Type C1 in Apoe-/- Mice.

Nanoparticles Containing a Liver X Receptor Agonist Inhibit Inflammation and Atherosclerosis

Activation of Liver X Receptor Β-Enhancing Neurogenesis Ameliorates Cognitive Impairment Induced by Chronic Cerebral Hypoperfusion.

Synthesis and Identification of New Flavonoids Targeting Liver X Receptor Β Involved Pathway As Potential Facilitators of Aβ Clearance with Reduced Lipid Accumulation.

Overexpression of NgBR Inhibits High-Fat Diet–induced Atherosclerosis in ApoE-deficiency Mice

NO-1886 Upregulates ATP Binding Cassette Transporter A1 and Inhibits Diet-Induced Atherosclerosis in Chinese Bama Minipigs

Notoginsenoside R1 Attenuates Atherosclerotic Lesions in ApoE Deficient Mouse Model.

Synthetic Liver X Receptor Agonist T0901317 Inhibits Semicarbazide-Sensitive Amine Oxidase Gene Expression and Activity in Apolipoprotein E Knockout Mice

A Novel Agonist Of Ppar-Gamma Based On Barbituric Acid Alleviates The Development Of Non-Alcoholic Fatty Liver Disease By Regulating Adipocytokine Expression And Preventing Insulin Resistance

cRGD-platelet@MnO/MSN@PPARα/LXRα Nanoparticles Improve Atherosclerosis in Rats by Inhibiting Inflammation and Reducing Blood Lipid

Xyloketal B Reverses Nutritional Hepatic Steatosis, Steatohepatitis, and Liver Fibrosis Through Activation of the PPARα/PGC1α Signaling Pathway.

Xyloketal B Reverses Nutritional Hepatic Steatosis, Steatohepatitis, and Liver Fibrosis through Activation of the PPAR alpha/PGC1 alpha Signaling Pathway

Targeting Macrophage Liver X Receptors by Hydrogel‐encapsulated T0901317 Reduces Atherosclerosis Without Effect on Hepatic Lipogenesis

Effect of Lipanthyl on Mrna Expression of Endothelin-1 and Nitric-Oxide Synthase in Atherosclerotic Vessel Wall in Rabbits.

A Novel Agonist of PPAR-γ Based on Barbituric Acid Alleviates the Development of Non-Alcoholic Fatty Liver Disease by Regulating Adipocytokine Expression and Preventing Insulin Resistance.

ZLJ-6, a Novel COX/5-LOX Inhibitor, Ameliorates Atherosclerosis by Reducing Macrophage Infiltration in ApoE(-/-) Mice

Discovery of Tissue Selective Liver X Receptor Agonists for the Treatment of Atherosclerosis Without Causing Hepatic Lipogenesis.

Oral nanoparticles containing naringenin suppress atherosclerotic progression by targeting delivery to plaque macrophages

Xyloketal B Attenuates Fatty Acid-Induced Lipid Accumulation Via the Srebp-1c Pathway in Nafld Models

Targeted Nanotherapeutics Encapsulating Liver X Receptor Agonist GW3965 Enhance Antiatherogenic Effects Without Adverse Effects on Hepatic Lipid Metabolism in Ldlr−/− Mice